News

February 10, 2021February 10, 2021

CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomas

News

The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for treating adults with relapsed or refractory large B-cell lymphoma (LBCL) who have had ... Read more

February 8, 2021February 8, 2021

Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show

News

First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival and delay disease progression in patients with advanced non-small cell lung cancer (NSCLC) compared with ... Read more

February 5, 2021February 5, 2021

Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumors

News

Cytovia Therapeutics has entered into a licensing agreement with the National Cancer Institute (NCI) to develop a new “off-the-shelf” immunotherapy for solid tumors. The immunotherapy is based on “natural killer” ... Read more

February 3, 2021February 3, 2021

Keytruda Closer to Expanded EU Approval for Resistant Hodgkin’s Lymphoma

News

Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose ... Read more

February 1, 2021February 1, 2021

First Glioblastoma Patient Dosed in Phase 2 Trial Testing PVSRIPO Plus Keytruda

News

The first patient has been dosed in a Phase 2 trial assessing the safety and preliminary efficacy of PVSRIPO in combination with Keytruda (pembrolizumab) as a treatment for people with recurrent ... Read more

January 29, 2021January 29, 2021

EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancers

News

The European Commission has approved Keytruda (pembrolizumab) as a first-line therapy for adults with metastatic colorectal cancer whose tumors have certain genetic features, the company announced. The genetic features, according to a press ... Read more

January 27, 2021January 27, 2021

Bavencio Approved in EU as First-line Maintenance Therapy for Bladder Cancer

News

The European Commission (EC) has approved Bavencio (avelumab) as a first-line maintenance treatment for adults with advanced urothelial carcinoma, the most common form of bladder cancer, whose disease did not progress after ... Read more

January 25, 2021January 25, 2021

Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer

News

Retifanlimab is under review in the U.S. as a treatment for advanced squamous cell carcinoma of the anal canal (SCAC), a rare cancer of the digestive system, in adults who ... Read more

January 22, 2021January 22, 2021

FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancers

News

The U.S. Food and Drug Administration (FDA) has accepted for review — under priority status — two applications requesting the approval of Opdivo (nivolumab) for treating several types of gastric ... Read more

January 20, 2021January 20, 2021

Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

News

First-line therapy with a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) significantly prolongs the survival of people with inoperable hepatocellular carcinoma (HCC) — the most common form of liver cancer ... Read more